Judge Doherty extends deadline to file against Actos in MDL 2299

Judge Rebecca Doherty, who is overseeing the Actos multidistrict litigation (MDL) suit 2299 in Louisiana, extended the shutterstock_451629811deadline for plaintiffs to file suits against Takeda Pharmaceuticals.

Judge Doherty cited the large number of cases expected to be filed, and the necessity of gathering enough information in each case. She issued a scheduling order on July 13th to start the first Actos trial in November 2014.

Starting in 2010, several studies found that Actos was linked to an increased rate of bladder cancer in patients with Type 2 diabetes. In 2011, France and Germany both banned the drug, claiming the association between bladder cancer and Actos was too great. That same year, the FDA issued a black box warning on Actos (pioglitazone) – the strongest warning a drug can receive.

While studies continue to connect the drug to bladder cancer, researchers insist that the risks are still not too great. Bladder cancer is relatively rare, but patients with Type 2 diabetes have a 40% increased risk of developing that type of cancer without any drug associations. Some studies, including the recent Kaiser Permanente study, do not take additional risk factors like smoking and weight into account. Overall, studies find that Actos increases the risk of bladder cancer after 2 or more years of use, but have not found that Actos specifically causes bladder cancer.

Type 2 diabetes patients who have been diagnosed with bladder cancer, and have taken Actos, are urged to speak with a lawyer regarding this suit. Anyone who is currently taking Actos should speak candidly about detrimental side effects – which can include increased risk of heart diseases, bladder cancer, and even diabetic macular edema – with their physician.

If you are in South Carolina, and you or a loved one have taken Actos and have been diagnosed with bladder cancer, please contact the experienced lawyers at Strom Law.


Share on facebook
Share on twitter
Share on linkedin

Follow us

Sign Up For Our Newsletter!